Chronic lymphocytic leukemia (CLL) is a common type of blood cancer in adults. This study, called the ARISE study, looks at a medicine named **acalabrutinib (CalquenceTM)**. Acalabrutinib is used to treat CLL by blocking a specific protein (Bruton Tyrosine Kinase or BTK) that helps cancer cells grow. This study is happening in Italy and involves collecting information from people with CLL who started taking acalabrutinib between May 2021 and April 2022. The main goal is to see how long patients stay on the medicine and why they might stop taking it. This is not an experiment with new treatments, but a way to see how the medicine works in real life.
NCT06205498
AstraZeneca
24 January 2024
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Congrats! You have your own personal workspace now.